Innoviva (INVA) Capital Expenditures (2010 - 2026)
Innoviva's (INVA) quarterly Capital Expenditures came in at $492000.0 in Q1 2026, down 56.11% on a QoQ basis from $1.1 million in Q3 2025.
Innoviva (INVA) Capital Expenditures (2010 - 2026) Analysis & Trends
Innoviva (INVA) has 14 years of Capital Expenditures data on file, last reported at $492000.0 in Q1 2026.
- Quarterly Capital Expenditures changed N/A year-over-year to $492000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (up 597.41% YoY) and the FY2025 annual result came in at $1.1 million, up 318.89% from the prior year.
- Capital Expenditures eased to $492000.0 in Q1 2026, from $1.1 million in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $1.1 million in Q3 2025 to a low of $9000.0 in Q1 2022.
- A 5-year average of $278875.0 and a median of $146500.0 in 2022 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2023 — Capital Expenditures soared 687.88% — and 2024, when it increased 3.85%.
- Tracing INVA's Capital Expenditures over 5 years: stood at $33000.0 in 2022, then soared by 687.88% to $260000.0 in 2023, then advanced by 3.85% to $270000.0 in 2024, then soared by 315.19% to $1.1 million in 2025, then slumped by 56.11% to $492000.0 in 2026.
- The last three Capital Expenditures figures came in at $492000.0 (Q1 2026), $1.1 million (Q3 2025), and $270000.0 (Q3 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Innoviva | 1.54 Bn | 968.79 Mn | 90.62 Mn | 429,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 429,000.00 |
| Jun 30, 2026 | 429,000.00 |
| Mar 31, 2026 | 492,000.00 |
| Mar 31, 2026 | 492,000.00 |
| Sep 30, 2025 | 1.12 Mn |
| Sep 30, 2025 | 1.12 Mn |
| Sep 30, 2024 | 270,000.00 |
| Sep 30, 2024 | 270,000.00 |
| Sep 30, 2023 | 260,000.00 |
| Sep 30, 2023 | 260,000.00 |
| Mar 31, 2023 | 33,000.00 |
| Mar 31, 2023 | 33,000.00 |
| Sep 30, 2022 | 33,000.00 |
| Sep 30, 2022 | 33,000.00 |
| Jun 30, 2022 | 13,000.00 |
| Jun 30, 2022 | 13,000.00 |
| Mar 31, 2022 | 9,000.00 |
| Mar 31, 2022 | 9,000.00 |
| Mar 31, 2020 | 13,000.00 |
| Mar 31, 2020 | 13,000.00 |